E
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases, including cystic fibrosis, Duchenne muscular dystrophy…
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel RNA-modulating therapies for rare and ultra-rare genetic diseases. The company's primary target is diseases caused by nonsense mutations, which are genetic alterations that prematurely stop protein synthesis. Eloxx's lead investigational drug, ELX-02, is designed to restore the production of functional proteins by enabling the ribosome to read through these premature stop codons, a process known as translation. Currently, ELX-02 is in Phase 2 clinical trials for cystic fibrosis patients with diagnosed nonsense mutations.
Eloxx operates in the biopharmaceutical market, primarily targeting patients with high unmet medical needs. The company employs a research and development strategy that focuses on identifying patient populations with nonsense mutations, establishing preclinical models, and navigating the regulatory pathways for Orphan Drug development. Eloxx's business model revolves around the development and commercialization of its proprietary small molecule compounds, which are designed to be disease-modifying therapies.
Revenue generation for Eloxx is anticipated through the successful development, regulatory approval, and commercialization of its drug candidates. The company also places a strong emphasis on patient advocacy, ensuring that patient needs are central to its drug development process.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2013
- Headquarters
- Watertown, United States
- Listing
- IPO 2016
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 71.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Orthopedic, Biotech and Pharma, Woman Founder, proteomics, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $66M | — | Undisclosed | ↗ |
| POST IPO DEBTDebt | Jul 2024 | $3.2M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$6.3M | — |
| 2025 | $0 | -100% | −$6.3M | — |
| 2024 | $6.4M | — | −$2.2M | -35% |
| 2023 | $0 | — | −$16M | — |
| 2022 | $0 | — | −$34M | — |
| 2021 | — | — | −$66M | — |
| 2020 | — | — | −$25M | — |
Growth signals
Latest recorded traffic for Eloxx Pharmaceuticals is 3.2K monthly website visits, up 88.2% over the last three months. Eloxx Pharmaceuticals's team declined 45.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Eloxx Pharmaceuticals in the Watertown ecosystem
The Eloxx Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cystic Fibrosis Foundation
Series B and later10 investors entered at this stage
Pontifax Funds
DSC Investment
Catalyst CEL Fund
EQT Life Sciences- DFDr. Phil Frost
OPKO Health
GF Securities
Quark Venture
Korea Investment Partners
Hercules Capital
Other known investors5 additional known investors
Sevion Therapeutics
Technion Israel Institute of Technology
Advent Life Sciences
China Everbright Limited- MVMedison Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Eloxx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eloxx Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









